Week In Review: BeiGene Signs $540 Million Deal For China Rights To Three HBV Candidates
July 25, 2020 at 14:21 PM EDT
Beijing's BeiGene in-licensed Greater China rights to three inhibitors for chronic hepatitis B virus from Assembly Bio in a $540 million agreement. BeiGene, which will make a $40 million upfront payment, is responsible for $500 million in milestones.
